6901 Diamond Investment

Release Date: July 8, 2026 Statement Date: July 7, 2026 Statement Time: 17:05:11 Company Code: 6901 Company Name: Diamond Investment

Subject: Announcement of changes in shareholdings and fair value of all investment targets, as well as net asset value per share, cash, and cash equivalents balance.

Applicable Clause: Clause 51 Factual Date: July 7, 2026

Details: 1. Factual Date: 07/07/2026 2. Company Name: Diamond Biotech Investment Co., Ltd. 3. Relationship with Company (Please enter '本公司' or 'Subsidiary'):本公司 4. Cross-shareholding Ratio: Not applicable 5. Reason for Occurrence: In accordance with the regulations stipulated in the letter No. 1121802934 issued by the Taiwan Stock Exchange Corporation on June 29, 2023, the company is required to disclose monthly updates on changes in shareholdings and fair value of all investment targets, as well as its net asset value per share, cash, and cash equivalents balance.

6. Response Measures: (1) The changes in shareholdings and fair value of investment targets held by the company in June 2026 are as follows:

(Unit: Shares; Thousand NTD)

Company Name June 2026 May 2026 Change in Fair Value Shares Shares Shares Change -------------------------- ------------ ------------ ------------- ------------ Glycomatrix (Co.) Ltd. 30,869,000 30,869,000 - 2,112,674 StemCyte International 32,937,150 32,793,150 144,000 (7,196) Ltd.

Theia Medical Technology 9,042,648 9,042,648 - 6,546 Co., Ltd.

Hsin Yao Biomedical 6,696,209 6,696,209 - 36,762 (Co.) Ltd.

EyeYon Medical Ltd. 59,018 59,018 - (1,357)

Tiandentai Agricultural 7,900,000 7,900,000 - (237) Biotech (Co.) Ltd.

Kendall Capital Partners N/A N/A N/A 8,892 I, L.P.

Bilayer Therapeutics, 915,540 915,540 - 9 Inc.

U-IEC (Co.) Ltd. 5,331,428 5,331,428 - 0

Rejuvenate Bio Inc. 1,498,801 N/A 1,498,801 39,808

Syncell Inc. 10,367,059 10,367,059 - 3,318

Diamond No.1 Investment 200,000,000 200,000,000 - 2,504 (Co.) Ltd.

Diamond High-Tech Investment 200,000,000 200,000,000 - 7,496 (Co.) Ltd. -------------------------------------------------------------------------------- Total Fair Value Change: 2,209,219 ===============================================================================

(2) The company's net asset value per share and cash and cash equivalents balance are as follows:

Date Net Asset Value per Share (NTD) Cash & Equivalents (NTD Thousand) --------------------- ------------------------------- ---------------------------------- June 30, 2026 14.41 2,533,476

7. Other Matters to be Disclosed: The company's primary investment targets are biotechnology-related stocks, whose stock prices and fair values are significantly influenced by research and development outcomes, leading to substantial volatility. Therefore, if the fair value changes decline during the year, the company's operating revenue may become negative.